Response rates to standard interferon treatment in HCV genotype 3a.

摘要: Background: Chronic Hepatitis C infection infects almost 130 to 170 million or approximately 2.2–3% of world’s population. HCV is one the main causes chronic liver disease leading progressive injury, fibrosis, cirrhosis and cancer. It also indications for transplantation worldwide. The objective study was determine response treatment with standard Interferon Ribazole in naive infected patients. Methods: This quasi-experimental carried out at Department Medicine, KRL General Hospital Islamabad, from January 2003 2005. A total 250 patients were enrolled this descriptive study. All anti positive, PCR positive RNA had 3a genotype. non-probability purposive sampling technique applied collect data. After taking a written informed consent; specially designed performa containing patient profile, family transmission, baseline laboratory values filled. Patients treated set protocol plus Ribavarin therapy (IFN alpha 2a, 3 mIU thrice weekly 24 weeks 1,000 1,200 mg/day) six months. Chi-Square tests used analyse Primary end point sustained virological (SVR) that assessed after months completion treatment. Results: Response rates studied over two years period. Out patients, 60 excluded; as 30 did not meet inclusion criteria, 23 lost follow. Seven declined the190 155 (81.6%) achieved End Treatment Complete (EOTCR) whereas 35 (18.4%) nonresponders (NR). These who showed complete followed assess viral response, which seen 112 (72.25%) 43 (27.7%) relapsers. co-related gender, ALT necro-inflammatory stage by biopsy, probable risk factors history. Conclusion: Management genotype 3a, lower SVR compared reported previous international local Keywords : HCV, Interferon, Rates, SVR.